# A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants

> **NCT05976360** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 38 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** Dupilumab (SAR231893)
- **DRUG:** Dupilumab (SAR231893)

## Key facts

- **NCT ID:** NCT05976360
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-02
- **Primary completion:** 2015-01-17
- **Final completion:** 2015-01-17
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2023-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05976360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05976360, "A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05976360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*